New pill shows promise for tough blood cancers in early trial
NCT ID NCT06846606
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This early-phase study tests an experimental oral drug called AUTX-703 in about 34 adults whose acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) have returned or not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and look for any signs that it can control the disease. Participants must have tried other therapies first.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope National Medical Center
Duarte, California, 91010, United States
-
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10021, United States
-
Ohio State University, The James Comprehensive Cancer
Columbus, Ohio, 43210, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14203, United States
-
Sarah Cannon Center for Blood Cancer at TriStar Centennia
Nashville, Tennessee, 37203, United States
-
UPENN Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, 19104, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27514, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.